The financials
Xeris Biopharma Holdings, Inc. by the numbers
Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $83M in Q1 2026 (quarter ended Mar 31, 2026), up 38% from the same quarter a year earlier. That came with a gross margin of 87% and net income of $2.2M (2.7% of revenue). For the full year FY2025, revenue was $292M (+44% year on year) and net income $554K. Its largest product in Jun 2026 was Recorlev at $57M, 62% of the disclosed total, well ahead of Gvoke at 24%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $83M | $60M | +38% |
| Gross profit | $73M | $51M | +41% |
| Operating income | $7.9M | −$3.1M | to a profit |
| Net income | $2.2M | −$9.2M | to a profit |
| Diluted EPS | $0.01 | −$0.06 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Recorlev | $57M | 62% |
| Gvoke | $23M | 24% |
| Keveyis | $12M | 13% |
| Royalty Contract And Other | $1.1M | 1.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $92.1M (+11%)
Recorlev grew +81% year on yearProduct Other -100% year on year
Segment Latestquarter on quarteryear on year
- Recorlev$56.8M$56.8MQoQ +14%year on year +81%+14%+81%
- Gvoke$22.5M$22.5MQoQ +8.4%year on year -3.9%+8.4%-3.9%
- Keveyis$11.7M$11.7MQoQ -1.8%year on year +1.7%-1.8%+1.7%
- Royalty Contract And Other$1.1M$1.1MQoQ +63%year on year -71%+63%-71%
- Product Other$0.00$0.00QoQ -year on year -100%--100%
Drug Manufacturers - Specialty & Generic
Ranks #14 of 29 by Smart Score